CXCR4 and neoplasm: In vivo and in vitro experiments show that AMD3100, a CXCR4 antagonist, targets the CXCR4/stromal cell-derived factor-1 axis by competitively binding CXCR4 to inhibit the proliferation and invasion of tumor cells (Phillips et al., 2003; Wang J. et al., 2020).